The Third Rock-launched Global Blood Therapeutics has rounded up $48 million to push into the clinic with an experimental therapy for sickle cell disease and set the stage for an IPO later this year--once they have proof-of-concept data for their drug in hand.
Yesterday's news that Moderna raised $450 million on the back of its preclinical R&D work--on top of the $500 million it already banked--stood out as the biggest new venture round recorded for an early-stage biotech like this. But it's still just a piece of the money that's been flowing into biotech over the past year--and a likely harbinger of more good things to come in 2015.
Superlatively well-funded biotech Moderna Therapeutics has raised another $450 million in venture cash, planning to staff up and buckle down on a slew of preclinical candidates that promises to transform patients' cells into drug factories.
Berkeley, CA's Aduro Biotech pulled in $51.4 million in Series D cash, fattening its wallet as the company works through mid-stage trials with a promising immuno-oncology pairing.
In early 2013, Roche signed a $595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now Chiasma is picking up the pieces, raising cash in hopes of submitting its drug to regulators this year.
Billions of dollars in new biotech investments are being made, R&D is being globalized more than ever before and new technologies and drug classes are moving fast through the clinic. FierceBiotech assesses what we believe are the 5 top trends to watch in the year ahead.
Startup Padlock Therapeutics has a novel approach to autoimmune disease that could reduce the need for immunosuppressants, and the biotech has $23 million in fresh cash to explore the idea.
After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.
Google Ventures is betting more and more on life sciences startups each year, and the well-funded financier tells The Wall Street Journal that's not going to change in the new year.
Novartis Venture Fund has stepped in to take the lead on a $34 million venture round for Redwood City, CA-based upstart Annexon Bioscience, which believes it has the inside track on a new treatment for Huntington's disease.